MedTrace Logo

Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy

NCT05393024 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2025-01-15

No results posted yet for this study

Summary

This is a retrospective/prospective observational study evaluating the efficacy and safety of Belantamab Mafotidin as a single agent in patients with Multiple Myeloma Relapse/Refractory (MMRR) treated in clinical pratice under compassionate use

Conditions

Interventions

DRUG

Belantamab mafodotin

MMRR patients included in Named Patient Program e Expanded Access Program

Sponsors & Collaborators

  • Fondazione EMN Italy Onlus

    lead OTHER

Principal Investigators

  • Maria Teresa Petrucci, MD · Policlinico Umberto I - Università 'Sapienza'

  • Massimo Offidani, MD · A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi di Ancona

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-22
Primary Completion
2024-08-12
Completion
2024-08-12

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05393024 on ClinicalTrials.gov